JP2025509950A - Ｐｉ３ｋ阻害剤の結晶形態及び塩ならびにその製造方法及びその使用方法 - Google Patents

Ｐｉ３ｋ阻害剤の結晶形態及び塩ならびにその製造方法及びその使用方法 Download PDF

Info

Publication number
JP2025509950A
JP2025509950A JP2024556116A JP2024556116A JP2025509950A JP 2025509950 A JP2025509950 A JP 2025509950A JP 2024556116 A JP2024556116 A JP 2024556116A JP 2024556116 A JP2024556116 A JP 2024556116A JP 2025509950 A JP2025509950 A JP 2025509950A
Authority
JP
Japan
Prior art keywords
crystalline form
peaks
compound
xrpd
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509950A5 (enExample
Inventor
ソニン ダワン，ニール
アベレラ ブレア，ジェームズ
ビー ペルニ，ロバート
リン ランドール，ジャレッド
ワン，シャオヤン
リ，メイチー
Original Assignee
トータス メディスンズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トータス メディスンズ インコーポレイテッド filed Critical トータス メディスンズ インコーポレイテッド
Publication of JP2025509950A publication Critical patent/JP2025509950A/ja
Publication of JP2025509950A5 publication Critical patent/JP2025509950A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024556116A 2022-03-24 2023-03-24 Ｐｉ３ｋ阻害剤の結晶形態及び塩ならびにその製造方法及びその使用方法 Pending JP2025509950A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022082752 2022-03-24
CNPCT/CN2022/082752 2022-03-24
PCT/CN2023/083760 WO2023179771A1 (en) 2022-03-24 2023-03-24 Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025509950A true JP2025509950A (ja) 2025-04-11
JP2025509950A5 JP2025509950A5 (enExample) 2026-04-01

Family

ID=86286092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556116A Pending JP2025509950A (ja) 2022-03-24 2023-03-24 Ｐｉ３ｋ阻害剤の結晶形態及び塩ならびにその製造方法及びその使用方法

Country Status (8)

Country Link
US (1) US20250197408A1 (enExample)
EP (1) EP4499642A1 (enExample)
JP (1) JP2025509950A (enExample)
KR (1) KR20250044815A (enExample)
CN (1) CN119212996A (enExample)
AU (1) AU2023240100A1 (enExample)
CA (1) CA3246202A1 (enExample)
WO (1) WO2023179771A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220079866A (ko) 2019-09-19 2022-06-14 토투스 메디신스 아이엔씨. 치료 접합체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220079866A (ko) 2019-09-19 2022-06-14 토투스 메디신스 아이엔씨. 치료 접합체

Also Published As

Publication number Publication date
KR20250044815A (ko) 2025-04-01
AU2023240100A1 (en) 2024-10-03
CA3246202A1 (en) 2023-09-28
CN119212996A (zh) 2024-12-27
EP4499642A1 (en) 2025-02-05
US20250197408A1 (en) 2025-06-19
WO2023179771A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP6317320B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
US10208065B2 (en) Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
US11958838B2 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-n,2-dimethylbenzofuran-3-carboxamide
BR112014022789B1 (pt) Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
CN106029659A (zh) 谷氨酰胺酶抑制剂
TW202035370A (zh) Mdm2抑制劑之製備方法及結晶型
CN107427503A (zh) 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
CN111132984A (zh) 凋亡信号调节激酶1抑制剂的盐及其晶型
CN110577543B (zh) 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
TW201920160A (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
CN120322431A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
US20250197408A1 (en) Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof
CN108778280B (zh) 一种GnRH受体拮抗剂的多晶型及其制备方法
JP2025143319A (ja) 化合物の塩及びその結晶形態
JP7618575B2 (ja) Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
CN115490640B (zh) 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
KR102967623B1 (ko) 액티빈 수용체 유사 키나아제 저해제의 염 및 결정 형태
KR20230026458A (ko) Shp2 억제제의 결정형 및 이의 조성물, 제조 방법과 용도
CN107922322B (zh) 化合物n-(3,5-二甲基苯基)-n′-(2-三氟甲基苯基)胍的制备方法
WO2025072796A1 (en) Pharmaceutical compositions and methods of use thereof
HK1231479B (zh) 6-((6，7-二甲氧基喹唑啉-4-基)氧基)-n，2-二甲基苯并呋喃-3-甲酰胺晶型

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260324